Cargando…

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research

This letter to the editor responds to comments on a recently published article on seroconversion rates after COVID-19 vaccination.

Detalles Bibliográficos
Autores principales:	Guven, Deniz C, Sahin, Taha K, Akın, Serkan, Uckun, Fatih M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632303/ https://www.ncbi.nlm.nih.gov/pubmed/36005823 http://dx.doi.org/10.1093/oncolo/oyac173

Ejemplares similares

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination
por: Guven, Deniz C, et al.
Publicado: (2022)

Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
por: Guven, Deniz C., et al.
Publicado: (2021)

Data-Driven identification of chemopreventive agents for breast cancer
por: GÜVEN, Deniz Can, et al.
Publicado: (2020)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies
por: Wiestner, Adrian
Publicado: (2022)

Research Progress on Pyroptosis in Hematological Malignancies
por: Lyu, Tianxin, et al.
Publicado: (2023)

The Research Advances of Aptamers in Hematologic Malignancies
por: Liao, Yongkang, et al.
Publicado: (2023)

Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese Patients
por: Sahin, Emre, et al.
Publicado: (2020)

Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience
por: Galvez, Carlos, et al.
Publicado: (2020)

Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2
por: Santarelli, Ignacio Martín, et al.
Publicado: (2023)

Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice
por: Ma, Haiqing, et al.
Publicado: (2015)

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
por: Tamariz-Amador, Luis-Esteban, et al.
Publicado: (2021)

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
por: Haggenburg, Sabine, et al.
Publicado: (2022)

A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies
por: Uckun, Fatih M., et al.
Publicado: (2014)

CORONAVIRUS ANXIETY LEVEL AND COVID 19 VACCINE ATTITUDE AMONG HEMATOLOGICAL MALIGNANCY PATIENTS
por: GÜVEN, Zeynep Tuğba, et al.
Publicado: (2022)

Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies
por: Sahin, Ugur, et al.
Publicado: (2019)

Immunophenotypic Profiling of Immune Cells in Patients with and without Hematologic Malignancies Affected By Sars-COV-2 Infection
por: Sanchez-Petitto, Gabriela, et al.
Publicado: (2021)

Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2021)

1590P Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies
por: Zakurdaeva, K., et al.
Publicado: (2021)

SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies
por: Ni, Bin, et al.
Publicado: (2022)

P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Tamariz-Amador, L.-E., et al.
Publicado: (2022)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

Coronavirus Anxiety Level and COVID-19 Vaccine Attitude Among Patients With Hematological Malignancies
por: Güven, Zeynep Tuğba, et al.
Publicado: (2023)

Evaluation of risk factors for mortality in hematological malignancy patients admitted to intensive care unit
por: Ileri, I, et al.
Publicado: (2015)

P1712: CORONAVIRUS ANXIETY LEVEL AND COVID 19 VACCINE ATTITUDE AMONG HEMATOLOGICAL MALIGNANCY PATIENTS
por: Güven, Z., et al.
Publicado: (2022)

Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation
por: Uckun, Fatih M.
Publicado: (2020)

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

SARS-CoV-2 infection in people with pre-existing liver disease: Further research is warranted
por: Verma, Henu Kumar, et al.
Publicado: (2021)

The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2021)

IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection
por: Villegas, Carolina, et al.
Publicado: (2020)

Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR
por: Pelcovits, Ari, et al.
Publicado: (2021)

Sars-CoV2 Antibody Responses in Patients with Hematological Malignancies Following Anti-CD20 Therapy
por: Guerra, Veronica A, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
por: Stuver, Robert, et al.
Publicado: (2022)

Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
por: Blennow, Ola, et al.
Publicado: (2022)

Cycle threshold predicted mortality in a cohort of patients with hematologic malignancies infected with SARS-CoV-2
por: Santarelli, Ignacio Martín, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ho7m3edp7jc5i3jgqt8k6t4lho